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Background: Genistein (Gen) exhibits anti-mutagenic and anti-metastatic activities in hepatoma cell lines. Gen has
suppressive effects on tumor growth and angiogenesis in nude mice. Gen suppresses the enzymatic activity of
matrix metalloproteinase (MMP)-9; however, the mechanism underlying its anti-invasive activity on hepatocellular
carcinoma (HCC) cells is unclear.
Methods: In this study, the possible mechanisms underlying Gen-mediated reduction of 12-O-Tetradecanoylphorbol-
13-acetate (TPA)-induced cell invasion and inhibition of secreted and cytosolic MMP-9 production in human hepatoma
cells (HepG2, Huh-7, and HA22T) and murine embryonic liver cells (BNL CL2) were investigated.
Results: Gen suppressed MMP-9 transcription by inhibiting activator protein (AP)-1 and nuclear factor-κ B (NF-κB)
activity. Gen suppressed TPA-induced AP-1 activity through inhibitory phosphorylation of extracellular signal-related
kinase (ERK) and c-Jun N-terminal kinase (JNK) signaling pathways, and TPA-stimulated inhibition of NF-κB nuclear
translocation through IκB inhibitory signaling pathways. Moreover, Gen suppressed TPA-induced activation of ERK/
phosphatidylinositol 3-kinase/Akt upstream of NF-κB and AP-1.
Conclusions: Gen and its inhibition of multiple signal transduction pathways can control the invasiveness and
metastatic potential of HCC.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third most frequent cause of cancer-
related mortality worldwide, with 6,000,000 new cases
diagnosed annually [1,2]. HCC is prevalent in Sub-Saharan
Africa and Southeast Asia, including Taiwan. HCC is asso-
ciated with various risk factors, including chronic infection
with hepatitis B or C viruses, environmental carcinogens,
chronic alcohol abuse, and non-alcoholic fatty liver disease
[2,3]. HCC is a hypervascular tumor, commonly involving
venous invasion, and HCC often progresses to intra- and* Correspondence: yehcc0530@gmail.com
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reproduction in any medium, provided the orextra-hepatic metastases [4]. Invasion and metastasis of
cancer cells are the primary causes of cancer deaths, which
are complicated processes involving proteolytic enzymes
that participate in the degradation of environmental
barriers such as the extracellular matrix and basement
membrane. Among these enzymes, the matrix metallo-
proteinases (MMPs), which comprise a family of zinc-
dependent endopeptidases, are intimately involved in
the invasion and metastasis of various tumor cells [5,6].
The MMP family is involved in extracellular matrix deg-
radation and is also associated with malignancy and
metastasis. The MMP-9 gene is strongly expressed in inva-
sive HCC [7], and the MMP-9 protein content in HCC is
greater than in the surrounding liver parenchyma. There-
fore, MMP-9 may be used as a marker for the invasiveness
and metastatic potential of HCC [7]. The activity of MMP-
9 is tightly controlled, with regulation occurring primarily
at the transcriptional level [5]. The MMP-9 promoter istd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ments, including nuclear factor-κB (NF-κB) and activator
protein (AP)-1 elements [8-10].
12-O-Tetradecanoylphorbol-13-acetate (TPA) is one of
the most widely used agents for studying the mechanisms
of carcinogenesis [11]. TPA exhibits numerous biological
effects by altering gene expression, a process that involves
activation of protein kinase C (PKC) [12]. In addition
to carcinogenesis, TPA induces MMP-9 expression via
PKC-dependent activation of the Ras/extracellular signal-
regulated protein kinase (ERK) signaling pathway, thus
increasing the invasiveness of cell lines [13]. Previous
reports have demonstrated that TPA-activated NF-κB and
AP-1 activities, and increased MMP-9 expression in
response to NF-κB activation, are associated with tumor
metastasis [14].
Genistein (Gen; 5,7,4′-trihydroxyisoflavone), a soybean-
derived isoflavone, has been identified as a potential cause
for the low incidence of certain types of tumors, such as
lung [15], breast, gastric, colon, and prostate cancers, and
HCC [9,15-19]. Gen is also a principal chemopreventive
component of soy and exerts a wide array of chemopre-
ventive activities in each stage of multistep carcinogenesis
[20,21]. Previous studies [20,22] showed that Gen is a
promising agent for inhibiting the metastatic potential of
HCC. Gen may affect HCC progression as a result of its
effects on cell cycle progression and apoptosis [16,22];
however, there are no reports on the mechanism of the in-
hibitory effects of Gen on TPA-induced invasion and
MMP-9 expression. Herein, we demonstrate that the sup-
pression of TPA-induced MMP-9 activity by Gen occurs




Genistein (Sigma Chemical Co., St. Louis, MO, USA) was
dissolved in 0.1 M Na2CO3 to create a 10-mM stock solu-
tion. TPA (Sigma-Aldrich, St. Louis, MO) was prepared in
phosphate-buffered saline (PBS; 137 mM NaCl, 1.4 mM
KH2PO4, 4.3 mM Na2HPO4, 2.7 mM KCl, pH 7.2). For
analysis of the signaling pathways involved in TPA-induced
DNA-binding of AP-1 and NF-κB, we also treated HepG2
cells with the p38 inhibitor SB203580 (SB), the MEK/ERK
inhibitor PD98059 (PD), the JNK inhibitor JNKI, the IKK
inhibitor BMS (AKTI), LY294002 (LY, an Akt inhibitor)
and bisindolylmaleimide (GF, GF109203X, a PKC inhibi-
tor) were purchased from Sigma-Aldrich to block these
pathways.
Cell culture and TPA treatment
Human hepatoma cell lines (HepG2, Huh-7, and HA22T)
and murine embryonic liver cells (BNL CL2) were main-
tained in Dulbecco’s modified Eagle medium (DMEM; LifeTechnologies, Gaithersburg, MD, USA) and supplemented
with 10% fetal bovine serum (FBS; HyClone, Logan, UT,
USA). The cells were transiently transfected with 5 μg
of plasmid DNA using SuperFect transfection reagent
(Qiagen, Valencia, CA, USA). TPA (Sigma-Aldrich) was
prepared in PBS (137 mM NaCl, 1.4 mM KH2PO4,
4.3 mM Na2HPO4, and 2.7 mM KCl, pH 7.2). HepG2,
Huh-7, HA22T, and BNL CL2 cells were cultured in
25-cm2 flasks at 37°C. The flasks were immediately
capped and sealed with parafilm to minimize evapor-
ation. Cell growth was measured using a modified
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) assay. HepG2 cells were resuspended with
100 μL in 96-well plates and cultured with or without
80 μM TPA and Gen, incubated for 24 h, then 20 μL MTT
was added to each well and incubated at 37°C for 4 h. The
supernatant was removed, 200 μL dimethyl sulfoxide
(DMSO) was added to each well to solubilize the formazan
product, and the absorbance was measured at 470 nm
using a microplate reader (Sigma).
Wound healing assay
Hepatoma cell lines were grown to 90% confluence in a
6-well plate at 37ºC in a 5% CO2 incubator. A wound was
created by scratching cells with a sterile 200 μL pipette tip,
then the cells were washed twice with PBS to remove
floating cells and added to serum-free medium. Photos of
the wound were obtained via microscopy under 100×
magnification.
Invasion assay
Cell invasion was assessed using Matrigel-coated film
inserts (8-μm pore size) fit into 24-well invasion cham-
bers (Becton-Dickinson Bioscience, Franklin Lakes, NJ,
USA). HepG2 cells (5 × 104) were suspended in 200 μL
of DMEM and added to the upper compartment of an
invasion chamber in the presence or absence of 80 μM
TPA; DMEM (500 μL) was added to the lower chamber.
The chambers were incubated at 37ºC in a 5% CO2
atmosphere. The filter inserts were removed after a 24-h
incubation period, and cells on the upper surfaces of the
filters were removed with cotton swabs. Cells on the
lower surfaces of the filters were stained with crystal
violet, and the number of cells was determined with the
use of a microscope. Final values were calculated as the
mean of the total number of cells from 3 filters.
Zymography
Gelatin zymography was used for determination of expres-
sion and activities of MMP-9 in TPA-treated (with or with-
out Gen) human HepG2 cells. HepG2 cells were seeded in
100-mm plates using serum-free medium and pretreated
with TPA and different concentrations of Gen. After incu-
bation for 24 h, the conditioned media were collected and
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using the Bio-Rad protein assay (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). Culture supernatants were subjected
to electrophoresis on gelatin substrate gels (10% sodium
dodoecyl sulfate [SDS]-polyacrylamide gels containing
1 mg/mL gelatin). Subsequently, the gels were treated
with 2.5% Triton X-100 for 30 min, followed by incuba-
tion for 24 h at 37°C in a buffer containing 100 mM
Tris–HCl, pH 7.4, 0.15 M NaCl, and 15 mM CaCl2.
The gels were stained with Coomassie Blue R-250 and
then destained with water until emergence of clear
zones that indicated proteolytic activity against a blue
background.Luciferase assay
Wild-type sequences were obtained for NF-κB (GGAA
TTCCCC) and AP-1 (TGAGTCA) sites. Reporter plas-
mids (pNF-κB-Luc and pAP-1-Luc) were purchased from
Stratagene (La Jolla, CA, USA). Plasmid DNAs were pre-
pared with a Qiagen Plasmid Midi Kit (Qiagen). The
MMP-9-Luc plasmid was kindly provided by Dr. C.K.
Glass [23]. Hepatoma cell lines were treated with 80 μM
TPA for 8 h, and luciferase activity was determined as pre-
viously described [14]. Briefly, HepG2 cells in each well
were washed with PBS and at lysed with 50 μL of passive
lysis buffer (Promega, Madison, WI, USA) at various time
points after treatment. Lysates were transferred to 96-well
white plates and substrate was added (Promega) to assess
the luciferase activity with a microplate reader (Synergy
HT, Bio-Tek, Winooski, VT, USA). Relative luciferase
activity was calculated by dividing relative luciferase
units of MMP-9, NF-κB, or AP-1 reporter plasmid-
transfected cells by the relative luciferase units of pGL3-
basic–transfected cells.Preparation of nuclear extracts and electrophoretic
mobility shift assay
HepG2 cells were treated with 80 μM TPA and 10–40 μM
Gen. Nuclear extracts were prepared as described previ-
ously [24]. Briefly, cells were stimulated, harvested by
centrifugation, washed twice with cold PBS, and then
nuclear extracts were prepared using NE-PER reagent
(Pierce, Rockford, IL, USA), according to the manufac-
turer’s instructions. Biotin-labeled complementary oligo-
nucleotides corresponding to NF-κB and AP-1 binding
sites were annealed. Biotinylated electrophoretic mobility
shift assays (EMSAs) were performed as previously de-
scribed [8], and gels were transferred to nylon membranes
after electrophoresis. Membranes were blocked in solution
and detected with alkaline phosphatase-conjugated strep-
tavidin (Chemicon, Australia) followed by chemilumines-
cence (Roche, Germany).Western blot analysis
Hepatoma cells were treated with 80 μM TPA and
10–40 μM Gen and lysed in 250 μL of sample buffer
(62.5 mM Tris–HCl, 2% SDS, 10% glycerol, 50 mM dithio-
threitol, and 0.1% bromophenol blue, pH 6.8). We also
collected the supernatants from cultures treated with
80 μM TPA and Gen. The supernatants were concentrated
40-fold with a Minicon filter (Millipore, Billerica, MA,
USA) with a 15-kDa cutoff pore diameter. Protein concen-
trations were determined with a BCA Protein Assay Kit
(Pierce, Rockford, IL, USA). To investigate the different cell
fractions, the cells were scraped into 2 mL of buffer A
(20 mmol/L Tris HCl, pH 7.5, 0.25 mol/L sucrose,
10 mmol/L EGTA, 2 mmol/L EDTA, 20 μg/mL leupeptin,
10 μg/mL aprotinin, and 200 μmol/L phenylsulfonyl
fluoride) at 4°C and were sonicated and separated into
cytosolic fraction and membrane fraction as described
previously [25]. The cytoplasmic extracts (cytosol) were
prepared using Cytoplasmic Extraction Reagent (Pierce),
according to the manufacturer’s instructions. For transloca-
tion of p65, the protein concentrations of p65 in cytoplas-
mic extracts and nuclear extracts were detected by western
blotting. Proteins (10 μg for cell lysates; 40 μg for superna-
tants) were separated using 10% SDS-polyacrylamide gel
electrophoresis, and protein bands were transferred elec-
trophoretically to nitrocellulose membranes. Membranes
were probed with polyclonal antibodies against p65, MMP-
9, epidermal growth factor receptor (EGFR), PKCα, PKCβ,
PKCγ, Akt, phosphatidylinositide kinase 3 (PI3K), IκB-α,
phosphorylated IκB-α, c-Jun N-terminal kinase (JNK),
phosphorylated JNK, p38, phosphorylated p38, extracellu-
lar signal-related kinase (ERK), phosphorylated ERK, and
β-actin (Cell Signaling Technology, Beverly, MA, USA).
Bound antibodies were detected with peroxidase-
conjugated anti-rabbit antibodies followed by chemilu-
minescence (ECL System; Amersham, Buckinghamshire,
UK) and autoradiographic exposure. The intensities of gel
bands were calculated with a Gel-Pro Analyzer.
Statistical analysis
One-way analysis of variance (ANOVA) was used to deter-
mine whether mean values differed significantly (p < 0.05).
If the means were significantly different, a Tukey-Kramer
post-hoc multiple group comparison test was used to com-
pare individual groups. Data are shown as mean ± stand-
ard error of the mean (SEM).
Results
Gen inhibited TPA-induced invasion and migration in
human hepatoma cells
In vitro invasion and migration assays, including trans-
well and wound healing assays, were used to determine
the inhibitory effect of Gen on the invasive potency of hu-
man hepatoma cell lines (HepG2, Huh-7, and HA22T)
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whether Gen could inhibit TPA-induced migration on the
surface of the tissue culture plate, we performed wound
healing experiments. As shown in Figure 1A, migration ofFigure 1 Effect of genistein (Gen) on TPA-induced migration in hepat
HepG2 (A), Huh-7, and HA22T and liver cells BNL CL2 (B) were treated with
incubated for 24 h. Photos of the wound were taken using microscopy unHepG2 cells was increased by TPA incubation and inhib-
ited by 20 μM and 40 μM of Gen.
HepG2 cells were also treated with TPA and Gen in an
invasion chamber to assess the effects of Gen on TPA-oma cell lines. For the wound healing assay, hepatoma cell lines
80 μM TPA and different concentrations of Gen in 6-well plates and
der 100× magnification.
Figure 2 (See legend on next page.)
Wang et al. BMC Complementary and Alternative Medicine 2014, 14:26 Page 5 of 12
http://www.biomedcentral.com/1472-6882/14/26
(See figure on previous page.)
Figure 2 Effect of genistein (Gen) on TPA-induced cell invasion. For the invasion assays, hepatoma cell lines HepG2 (A), Huh-7, and HA22T
and liver cells BNL CL2 (B) (5 × 104) were resuspended in 200 μL of DMEM and added to the upper compartment of Matrigel invasion chambers
supplemented with medium and treated with 80 μM TPA with or without different concentrations of Gen. After 24-h incubation, the total
number of cells on the lower surface of the insert chambers was stained with crystal violet and counted under a microscope (200× magnification).
Quantification of cell invasion assay. HepG2 (C), Huh-7, HA22T cells and liver cells BNL CL2 (E) were treated with 5–40 μM or 20 μM of Gen for 24 h.
Cell viability of HepG2 (D), Huh-7, HA22T and BNL CL2 cells (F) was determined by MTT assay. Results are expressed as fold invasion and presented as
the total number of invasive cells in treated cells relative to untreated cells. Values represent the mean ± SEM of 3 independent experiments. *p < 0.01
compared to TPA-treated cells.
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of the other 3 cell lines (Figure 1B). The migration of
human hepatoma cell lines (Huh-7 and HA22T) was in-
duced by TPA incubation and inhibited by treatment
with Gen at 20 μM. However, liver cells (BNL CL2) were
not affected by TPA incubation and treatment with Gen
at 20 μM.
We calculated the resulting number of invasive cells.
The results of TPA-induced cell invasion from the trans-
well assays are illustrated in Figure 2A and B. TPA in-
duced a 15 − 20-fold increase in the number of invasiveFigure 3 Effect of genistein (Gen) on TPA-induced MMP-9 expression
cultures after 24 h and analyzed by gelatin zymography (A). Cells were cul
treated with 80 μM TPA for 16 h in Hep G2 (B) and others cell lines (C). W
(supernatant) and MMP-9 expression in the cytosol. Values represent the m
TPA-treated cells.HepG2, Huh7, and HA22T cells that migrated through
the Matrigel-coated filters. This phenomenon was signi-
ficantly inhibited by Gen in a concentration-dependent
manner in HepG2 cells (Figure 2C). Quantitative data de-
rived from 3 independent experiments showed that Gen
effectively inhibited the invasion of HepG2 cells elicited by
TPA (Figure 2C). Similar results were obtained in the
other human hepatoma cell lines (Huh-7 and HA22T).
However, invasion was not effected by TPA incubation
and Gen treatment in the BNL CL2 liver cells (Figure 2B).
Taken together, these results showed that Gen inhibitedin hepatoma cell lines. Conditioned medium was collected from
tured in 25-cm2 flasks, pretreated with 10–40 μM Gen for 1 h, then
estern blot analysis showed MMP-9 secretion into the culture medium
ean ± SEM of 3 independent experiments. *p < 0.01 compared to
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essential invasive properties needed for tumor metastasis.
As illustrated in Figure 2D, the cytotoxicity of TPA and
Gen was evaluated using the MTT assay. No cytotoxic
effects were observed for 5–40 μM Gen in HepG2 cells
(Figure 2F).Effect of Gen on TPA-induced MMP-9 expression and
activity
Tumor invasion requires increased expression of MMP-9.
To examine whether gelatinolytic MMP activity in hepa-
toma cells could be activated by TPA, we performed zymo-
graphic analysis. Figure 3A shows that treatment with TPA
for 24 h significantly increased MMP-9 expression in
hepatoma cell lines (HepG2, Huh-7, and HA22T), which
was suppressed by Gen. However, the gelatinolytic activity
of MMP was not expressed in murine embryonic liver cells
(BNL CL2). Gen-mediated suppression of TPA-induced
MMP-9 expression resulted from increased MMP-9 levels
in the culture medium (supernatant) and cytosol in a
concentration-dependent manner (Figure 3B). In addition,
20-μM Gen-mediated suppression of TPA-induced MMP-
9 expression resulted from increased MMP-9 concen-
trations (Figure 3C). Moreover, as shown in Figure 4, GenFigure 4 Effect of genistein (Gen) on TPA-induced MMP-9−, NF-κB−, a
cells treated with increasing concentrations of Gen were transfected with (
luciferase gene. After 16-h treatment with 80 μM TPA, cell lysates were assa
that of untreated transfected cells. Values represent the mean ± SEM of 3 indramatically inhibited TPA-induced EGFR expression in
Hep G2 cells.Effect of Gen on TPA-activated transcription of MM-9, NF-κB,
and AP-1 promoters
To determine whether the transcriptional activities of
MMP-9, NF-κB, and AP-1 are regulated by TPA, we exam-
ined the promoter activity of the NF-κB and AP-1 genes
using luciferase assays. The cells were treated with TPA
(with or without Gen) for 16 h, and promoter activity was
measured by luciferase assay. Figure 4A shows that the
MMP-9 promoter was increased approximately 4-fold by
TPA in HepG2 cells relative to the control MMP-9
promoter-transfected cells, and the activated promoter
was suppressed by Gen in a dose-dependent manner
and significantly suppressed at concentrations ≥10 μM.
Figure 4B shows that the AP-1 promoter increased ap-
proximately 4-fold over the activity in AP-1–transfected
cells in response to TPA, which was also inhibited by
Gen in a dose-dependent manner and significantly sup-
pressed at concentrations ≥10 μM. As shown in Figure 4C,
the NF-κB promoter activity was increased approxi-
mately 2.7-fold over that in NF-κB–transfected cells in
response to TPA, and this was inhibited by Gen in and AP-1–dependent luciferase reporter gene expression. HepG2
A) MMP-9−, (B) AP-1−, or (C) NF-κB containing plasmids linked to the
yed for luciferase activity. Results are expressed as fold activity over
dependent experiments. *p < 0.01 compared to TPA-treated cells.
Figure 5 Effect of genistein (Gen) on TPA-induced NF-κB and AP-1 activation and translocation of p65 in hepatoma cell lines. After
45 min, EMSAs of nuclear extracts of cells were performed. TPA induced AP-1 (A, B, C) and NF-κB (D, E, F) activation, which was inhibited by
Gen and different inhibitors (B, E). For translocation of p65, cells were pretreated with 20 μM Gen with or without inhibitors for 45 min before
incubation with TPA for 45 min. Then, nuclear and cytosolic extracts were prepared and subjected to western blotting with antibodies specific
for p65 translocation (G). Cells were pretreated with 20 μM Gen with or without inhibitors for 30 min before incubation with TPA for 45 min,
and then nuclear extracts were prepared as described in the Methods section.
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Figure 6 Effect of genistein (Gen) on TPA-induced EGFR, MAPK, IκB, AKT, PKC-signaling pathways in hepatoma cell lines. (A) Cells were
pretreated with 10 or 20 μM Gen for 30 min before incubation with 80 μM TPA for 45 min or 24 h (for EGFR), then whole-cell lysates were
prepared and subjected to western blotting with antibodies specific for phosphorylated PI3k, AKT, IκB, JNK, p38, and ERK as described in Methods
section. (B) HepG2 cells were cultured in serum-free media containing 80 μM TPA for 45 min, then the cell cytosolic and membrane fractions
were prepared and then the extracts were analyzed by western blots as described in Methods section. The values under each lane indicate
relative density of the band normalized to β-actin. All analyses were representative of at least three independent experiments. (C) The
gelatinolytic activities of MMP-9 were determined by gelatin zymography as described in Materials and Methods.
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concentrations ≥20 μM.
To determine whether the inhibitory effect of Gen in
TPA-treated cells leads to NF-κB and AP-1 inhibition,
the effects of Gen on TPA-stimulated NF-κB– and AP-
1–specific DNA-protein binding activity were exam-
ined. Biotinylated EMSAs showed that TPA increased
DNA-binding of NF-κB and AP-1 after 45 min. Treat-
ment with 20 μM Gen inhibited TPA-induced AP-1–
specific DNA-protein binding (Figure 5A and B), and
treatment with 20 μM Gen inhibited TPA-induced
NF-κB–specific DNA-protein binding compared to TPA-
induced cells (Figure 5D and E). We also used specific in-
hibitors to examine whether TPA-induced DNA-binding
of AP-1 and NF-κB. We found that TPA-induced DNA-
binding of AP-1 was decreased by inhibitors of p38 (SB),
JNK (JNKI), ERK (PD), and AKT (AKTI) (Figure 5C).
Furthermore DNA-binding of NF-κB was decreased by
inhibitors of IKK (BMS), JNK (JNKI), and AKT (AKTI) in
hepatoma cells (Figure 5F). We also used specific inhi-
bitors to examine the translocation of NF-κB p65. The
translocation was aborted by 20 μM Gen and inhibitors of
IKK (BMS), JNK (JNKI), and AKT (AKTI) (Figure 5G).Inhibitory effect of Gen on TPA-induced activation of
MAPKs, PI3K, Akt, and PKC
Mitogen-activated protein kinases (MAPKs) are known to
regulate AP-1 and NF-κB activation via multiple mecha-
nisms. Studies have shown that the MAPK, IκB, and PI3K/
Akt signaling pathways are involved in TPA-mediated in-
duction of EGFR and MMP-9 [26,27]. We investigated the
effects of Gen on TPA-induced phosphorylation of ERK,
p38, JNK, IκB, and PI3K/Akt activity in hepatoma cells.
Western blot analysis revealed that TPA alone caused a
significant increase in the phosphorylation of ERK, p38,
JNK, IκB, PI3K, and Akt compared to vehicle-treated con-
trols; this phosphorylation was inhibited by pretreatment
with Gen (Figure 6A). Our results showed that the TPA-
induced phosphorylation of MAPK, IκB, and PI3K/Akt in
cells treated with 20 μM Gen was decreased, with the ex-
ception of the phosphorylation of p38 and IκB with 20 μM
Gen. As illustrated in Figure 6, Gen markedly abrogated
TPA-induced MMP-9 enzyme activity through inhibition
of the MAPK, IκB, and PI3K/Akt signaling pathways.Discussion
Epidemiologic studies have demonstrated that the con-
sumption of fruits and vegetables can reduce the risk of
several types of human cancers [28]. Approximately 70% of
the drugs used for cancer treatment are derived from or
based on natural products [29,30]. A number of phyto-
chemicals can inhibit tumor metastasis and cell invasion
via suppression of MMP gene expression and enzymatic
activity. For example, curcumin interferes with the activity
of MMP-9, reducing degradation of the extracellular
matrix, which forms the basis of the angiogenic switch [31].
Hesperidin suppresses TPA-induced MMP-9 transcription
by inhibiting NF-κB activity [32], and pterostilbene inhibits
TPA-stimulated NF-κB and AP-1 transcriptional activities
[27]. Gen is a small, biologically active flavonoid that is
abundant in soy. Gen is best known for its ability to inhibit
cancer progression and metastasis. Consumption of Gen in
the diet has been linked to decreased rates of metastatic
cancer in a number of population-based studies [33]. In
HCC, Gen has anti-mutagenic activity [34] and induces
apoptosis [35]. In the present study, we showed for the first
time that Gen suppresses TPA-induced cell invasive activity
and MMP-9 expression by reducing tumor migration and
invasion of HCC.
Several stimulators increase the expression of MMP-9
via various signaling pathways and result in increased
invasiveness in cell lines. Specifically, TPA-induced MMP-
9 expression has been studied extensively in HCC cells
[14,27,36]. These studies suggest that TPA-induced MMP-
9 expression in HepG2 cells occurs by activating phos-
phorylation of MAPK, IκB, and Akt signaling pathways.
These pathways activate the transcription factors NF-κB
and AP-1. We previously reported that NF-κB and AP-1
are activated in TPA-induced MMP-9 expression via IκB
and MAPK pathways in HCC cells [14]. Another report
showed that NF-κB and AP-1 were activated following
TPA-induced MMP-9 activation though extracellular
signal-regulated MAPK and PI3K/Akt [27,37]. The pre-
sent study showed that Gen effectively suppressed TPA-
induced MMP-9 gene expression by suppressing the
MAPK/AP-1 and PI3K/AKT/NF-κB cascades, with con-
sequent suppression of tumor migration and invasion of
human hepatoma HepG2 cells.
EGFR autocrine/paracrine pathways contribute to a num-
ber of processes that are important in the development and
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angiogenesis, and metastatic spread. High expression of
EGFR has been observed in numerous human tumors,
including lung, colon, breast, head and neck, ovarian, blad-
der, and liver cancers, and has been shown to correlate with
advanced tumor stage and poor clinical prognosis [38-40].
The EGFR signaling pathway is associated with metastatic
properties, including cell motility, adhesion, and invasion
in vitro [41,42]. EGFR activates intracellular signaling
cascades, including Ras/Raf/MEK/ERK and PI3K/Akt, and
subsequently controls proliferation, migration, and apop-
tosis [43]. Activation of NF-κB and AP-1 is centrally
involved in the induction of the MMP-9 gene associated
with the invasion and metastasis of tumor cells by differ-
ent agents, including TPA and growth factors, such as
EGF [27,44,45]. There is a report that TPA induces EGFR
expression in HepG2 cells [27]. Thus, the regulation of
NF-κB and AP-1, downstream of the PI3K/Akt and
MAPK pathways, might be involved in Gen suppression of
TPA-induced MMP-9 expression and invasion in HepG2
cells.Conclusion
In conclusion, we provided evidence that Gen promotes
anti-invasive and anti-metastatic effects against TPA-
mediated metastasis via downregulation of MMP-9 and
EGFR and subsequent suppression of NF-κB and AP-1
transcription factors though inhibition of MAPK, IκB,
and PI3K/Akt signaling pathways. Therefore, we con-
clude that MMP-9 inhibitory activity of Gen and its
inhibition of multiple signal transduction pathways sug-
gest its therapeutic potential for controlling the invasive-
ness and metastasis of HCC.
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